Healing & Repair
BPC-157
← Back to Library
Site-only / unverified FDA safety flag Site-only / unverified Repair Angiogenesis
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or clinical-trial above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 5, 10, 15, 20 mg
Dosing window: Morning / Evening
Receptor / target: VEGFR2; NO
Properties: Dopamine Buffer
Pre-mixed: No
Site-sourced protocols
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-6 | 250mcg twice daily | Systemic Protocol. Administered subQ in the abdomen. Affects the entire body's inflammatory response. |
Site-provided protocol; not independently verified as label dosing unless graded otherwise on this page.
Alternative: Localized Injection
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-6 | 250mcg - 500mcg twice daily | Administered subQ as close to the injury site as safely possible (e.g., skin above the knee). |
Site-provided alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative: Injury Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-8 | 500mcg-1.5mg 2-3x daily | Inject as close to the injury site as safely possible. Can extend beyond 8 weeks if needed, but monitor for diminishing returns after week 8. |
Site-provided alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Protocol logic check
Protocol context: Repair protocols depend on injury type, timing, loading, inflammation, and angiogenesis risk. Rodent or cell data can suggest a mechanism, but it does not prove a human dose or replace rehab and diagnosis. Entry context: target (VEGFR2; NO); route Subcutaneous; timing Morning / Evening. Site-only/low dosing tables are hypotheses, not recommendations. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit. Compatibility is conditional: a reasonable solo compound can become inappropriate once a contraindicated partner is added. The logic is repair signaling, but the human evidence gap is the main limiter. Rodent and cell data can explain why people pair it with injury rehab, but it does not prove a human dose. Active cancer, abnormal vessel growth, anticoagulants, pregnancy, and poor injury diagnosis change the risk calculation.
Independent evidence
Independent safety notes: FDA lists BPC-157 among withdrawn nominated bulk substances with potential significant safety risks and limited safety information for proposed routes.
Regulatory status: unapproved or compounded peptide with FDA safety risk flag
Storage
No independently verified storage guidance found. Treat any site-sourced storage claim as unverified, and see the general storage guidance in the FAQ.
Contraindications (site-sourced)
- Active malignancy: BPC-157's pro-angiogenic mechanism (VEGFR2 upregulation) directly promotes tumor vascularization; contraindicated in any active cancer regardless of type. Site-only / unverified
- History of any cancer: the theoretical risk of stimulating residual or dormant tumor cells via angiogenesis warrants caution; assess risk-benefit with oncology history carefully. Site-only / unverified
- History of severe or recurrent histamine reactions: BPC-157 modulates mast cell activity and NO pathways that intersect with histamine signaling; subjects with mast cell activation syndrome (MCAS) or confirmed histamine intolerance require extra caution. Site-only / unverified
- Subjects currently on anticoagulant or antiplatelet therapy: BPC-157 has potential coagulation and vascular function effects; additive risk with blood thinners warrants monitoring. Site-only / unverified
- Autoimmune disorders: BPC-157's immune modulatory effects carry theoretical risk of unpredictable immune activation with chronic use; use with caution in subjects with active autoimmune conditions. Site-only / unverified
- Pregnancy: no human safety data; avoid. Site-only / unverified
- Breastfeeding: no human safety data; avoid. Site-only / unverified
- Known hypersensitivity to BPC-157 or any formulation excipients. Site-only / unverified
- Subjects receiving corticosteroid therapy: corticosteroids (e.g., prednisone) can decrease the effectiveness of BPC-157 and are identified as an interaction in clinical monograph literature. Site-only / unverified
- Proliferative vascular disorders: subjects with arteriovenous malformations, uncontrolled neovascularization, or other pathological vessel growth syndromes. Site-only / unverified
- Severe cardiovascular disease with labile blood pressure: BPC-157's NO-mediated vasodilatory effects may cause blood pressure fluctuations. Site-only / unverified
- Pediatric use: no safety data established. Site-only / unverified
Side effects (site-sourced)
- Lethargy or mild fatigue: the most commonly reported adverse effect; onset typically within the first 1-7 days; likely related to initial inflammatory modulation and systemic healing signal activation; self-resolving. Site-only / unverified
- Nausea and abdominal discomfort: reported in clinical monograph data; mild; particularly in first days of use. Site-only / unverified
- Injection site reactions: redness, swelling, irritation at subcutaneous injection site; rotate administration sites. Site-only / unverified
- Dizziness and headache: vasodilation-related from NO-pathway activation and angiogenic effects. Site-only / unverified
- Flushing or sensations of heat/cold: NO-mediated vasodilation; transient. Site-only / unverified
- Sleep disturbances: reported anecdotally and in compounded preparation monograph; onset within the first week; self-resolving. Site-only / unverified
- Appetite changes: mild; may increase or decrease appetite during early weeks. Site-only / unverified
- Anhedonia: reported by a small subset of highly sensitive individuals; associated with dopamine buffering effect; temporary during initial cycle days. Site-only / unverified
- Blood pressure changes: downward pressure changes from NO-mediated vasodilation; monitor in subjects with hypotension. Site-only / unverified
- Overproduction of nitric oxide (theoretical at very high doses): supraphysiologic NO levels can cause hypotension, oxidative stress, and cellular toxicity; at standard doses this is not a practical concern. Site-only / unverified
- Pathologic angiogenesis: serious but rare; pro-angiogenic properties that accelerate healing in normal tissue could theoretically support aberrant vessel formation in pathological contexts. Site-only / unverified
- Changes in coagulation or vascular response: potential influence on clotting pathways; particularly relevant when stacking with other angiogenic or vasodilatory compounds. Site-only / unverified
- Immune modulation effects: with chronic use at high doses; the magnitude and direction of immune activation are not fully characterized in humans. Site-only / unverified
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
TB-500 (Thymosin Beta-4)GHK-Cu (Copper Tripeptide-1)AHK-CuKPVACE-031MGF (Mechano Growth Factor)Ara-290Teriparatide (PTH 1-34)Melanotan IMelanotan IICartalax
Reported contraindicated combinations: